Söndag 8 December | 10:22:04 Europe / Stockholm

Bifogade filer

Kalender

Tid*
2025-10-31 08:00 Kvartalsrapport 2025-Q3
2025-08-22 08:00 Kvartalsrapport 2025-Q2
2025-05-20 N/A Årsstämma
2025-05-14 08:00 Kvartalsrapport 2025-Q1
2025-02-25 17:30 Bokslutskommuniké 2024
2024-10-31 - Kvartalsrapport 2024-Q3
2024-08-22 - Kvartalsrapport 2024-Q2
2024-06-12 - X-dag ordinarie utdelning DIABIO 0.00 SEK
2024-06-11 - Årsstämma
2024-05-31 - Kvartalsrapport 2024-Q1
2024-02-28 - Bokslutskommuniké 2023
2023-10-31 - Kvartalsrapport 2023-Q3
2023-09-22 - Extra Bolagsstämma 2023
2023-08-22 - Kvartalsrapport 2023-Q2
2023-05-12 - X-dag ordinarie utdelning DIABIO 0.00 SEK
2023-05-11 - Årsstämma
2023-05-11 - Kvartalsrapport 2023-Q1
2023-02-23 - Bokslutskommuniké 2022
2022-11-23 - Extra Bolagsstämma 2022
2022-11-16 - Kvartalsrapport 2022-Q3
2022-08-23 - Kvartalsrapport 2022-Q2
2022-05-12 - X-dag ordinarie utdelning DIABIO 0.00 SEK
2022-05-11 - Årsstämma
2022-05-11 - Kvartalsrapport 2022-Q1
2022-02-23 - Bokslutskommuniké 2021
2021-10-29 - Kvartalsrapport 2021-Q3
2021-08-27 - Kvartalsrapport 2021-Q2

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Diagonal Bio är verksamt inom bioteknik. Bolaget utvecklar en plattform under namnet Panviral för att detektera och diagnostisera små sektioner av patogengenom, som exempelvis virus, bakterier och svampar. Utöver huvudverksamheten erbjuds även service och tillhörande kringtjänster. Verksamheten drivs med störst närvaro inom Sverige med huvudkontor i Lund.
2024-10-03 12:15:00

Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") has partnered with StallZet and Daniel Redén, one of Sweden's leading horse trotting training facilities, to conduct a pilot test using LAMPlify® to detect respiratory viral infections in StallZet's trotters. The three-month agreement takes effect immediately.

The pilot test is set to provide faster and more accurate, point-of-care diagnostics, potentially leading to quick action to increase the well-being of StallZet's trot training facility. StallZet manages over 190 horses and has a vast national and international network in the trotter and racehorse segment.

The collaboration with StallZet provides Diagonal Bio AB with a unique opportunity to expand the reach of its diagnostic platform, LAMPlify®. The renowned trainer and leader Daniel Redén at StallZet has long experience in trotting. Additionally, Daniel Redén and StallZet's vast network of professionals-including veterinarians, trainers, and specialists-will not only offer key connections but also valuable insights, aiding in the broader international adoption of the platform within the equestrian sector.

The collaboration and pilot test with StallZet allow Diagonal Bio to strengthen its partnerships within this sector. It involves cooperation in both the horse training environment and the veterinary field, with a focus on supporting equestrian events. This initiative opens up a new potential market while enhancing horse welfare, as early detection of respiratory infections is vital for maintaining healthy horses.

"At StallZet, we are always striving to give our horses the best possible care. Working with Diagonal Bio offers a unique opportunity to enhance horse welfare by quickly identifying health issues and ensuring top-quality care even before the break-out. I really see a huge opportunity for the entire horse industry including the different associations internationally start using LAMPlify® to identify sick horses before entering racetracks or arenas, and to be able to isolate them at their home stables in order not to infect others"- Daniel Redén, trainer at StallZet

"We are proud to partner with StallZet in this pilot. With their extensive experience and international network in horse competitions, StallZet is a valued partner to test our diagnostic platform. We believe our technology can make a significant impact, in horse welfare more broadly" - Karin Wehlin, CEO of Diagonal Bio AB (publ)

This press release contains inside information that Diagonal Bio AB (publ) is required to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication on October 3, 2024, at 12:15 CET.
For additional information about, please contact:
Karin Wehlin, CEO
Phone: +46 703 052488
E-mail: kw@diagonalbio.com

Certified Adviser
Svensk Kapitalmarknadsgranskning AB
E-mail: ca@skmg.se

About Diagonal Bio
Diagonal Bio AB was founded in 2020 and is a Swedish biotechnology company with headquarters and offices in Lund. The Company develops the PANVIRAL® platform to detect and diagnose small sections of pathogen genomes, for example viruses, bacteria and fungi. The Company was founded with the goal of reducing human suffering by revolutionising global diagnostics of pathogen-borne diseases with proprietary technology. Diagonal Bio's patented technology can also be used for the less regulated market segments via LAMPlify®.